-
公开(公告)号：DE3612212A1
公开(公告)日：1987-10-15
申请号：DE3612212
申请日：1986-04-11
Applicant: BASF AG
Inventor： GOERTZ HANS-HELMUT DR , KLIMESCH ROGER DR , LAEMMERHIRT KLAUS DR , LANG SIEGFRIED DR , SPENGLER REINHARD DR , SANNER AXEL DR
Abstract: Process for the preparation of solid pharmaceutical forms by mixing one or more pharmaceutical active compounds with one or more fusible, pharmacologically tolerated binders and, if required, other conventional pharmaceutical auxiliaries, at from 50 DEG to 180 DEG C., and subjecting the mixture to injection molding or extrusion and shaping, wherein the fusible binder used is a NVP polymer which contains not less than 20% by weight of NVP as copolymerized units, and, where they are present, all of whose comonomers contain nitrogen and/or oxygen.
-
公开(公告)号：AT77739T
公开(公告)日：1992-07-15
申请号：AT87104724
申请日：1987-03-31
Applicant: BASF AG
-
Patent Agency Ranking
公开(公告)号：DE3780059D1
公开(公告)日：1992-08-06
申请号：DE3780059
申请日：1987-03-31
Applicant: BASF AG
Inventor： GOERTZ HANS-HELMUT DR , KLIMESCH ROGER GUENTHER DR , LAEMMERHIRT KLAUS DR , LANG SIEGFRIED DR , SANNER AXEL DR , SPENGLER REINHARD DR
Abstract: Prodn. of solid pharmaceutical dosage forms is effected by mixing at least one active ingredient with at least one meltable binder andopt. other additives, and either injection moulding or extruding and shaping the mxit. at 50-180 deg.C.. The binder is a solvent free polymer of N-vinylpyrrolidone (NVP) comprising 20-100 wt.% NVP and 0-80 wt.% of N- and/or O-contg. comonomers. The polymer contains no more than 3.5 wt.% H2O.At least when the mxit. has a glass temp. above 130 deg.C, the polymer must be produced by polymerisation in an organic solvent or by polymerisation in an aq. medium using an organic peroxide initiator. The mixt. contains no added thermoplasts which are sparingly soluble in gastric juices.
-
公开(公告)号：DE2631779A1
公开(公告)日：1978-01-19
申请号：DE2631779
申请日：1976-07-15
Applicant: BASF AG
Inventor： LAEMMERHIRT KLAUS DR , PICH CLAUS HINRICH DR , SEELERT KURT DR
IPC: A61K9/00 , A61K31/635 , A61K47/32 , A61K9/08 , A61K31/505
Abstract: New clear, aq. sulphonamide/trimethoprim solns. contain (a) a water-soluble sulphonamide salt, (b) trimethoprim and (c) polyvinyl pyrrolidone with a K-value of 10-18 in water, opt. with the addition of further substances and/or solvents. Sulphonamide/trimethoprim solns. are provided for oral, parenteral or external application. The new solns. avoid the need for solvents with poor pharmaceutical acceptability (e.g., propylene glycol, glycerine formal, dimethylacetamide). The solns. also avoid extreme of pH (which can cause local pain on injection). Typical formulation contains 4 g. sulphamoxole sodium, 0.8 g. trimethoprim, 55 g. polyvinyl pyrrolidone (K-value 12), 0.8 g. sodium sulphite and water for injection to 100 ml.
-
公开(公告)号：CS268177B2
公开(公告)日：1990-03-14
申请号：CS253287
申请日：1987-04-08
Applicant: BASF AG
Inventor： GOERTZ HANS-HELMUT DR , KLIMESCH ROGER G DR , LAEMMERHIRT KLAUS DR , LANG SIEGFRIED DR , SANNER AXEL DR , SPENGLER REINHARD DR
Abstract: Process for the preparation of solid pharmaceutical forms by mixing one or more pharmaceutical active compounds with one or more fusible, pharmacologically tolerated binders and, if required, other conventional pharmaceutical auxiliaries, at from 50 DEG to 180 DEG C., and subjecting the mixture to injection molding or extrusion and shaping, wherein the fusible binder used is a NVP polymer which contains not less than 20% by weight of NVP as copolymerized units, and, where they are present, all of whose comonomers contain nitrogen and/or oxygen.
-
公开(公告)号：CS8702532A2
公开(公告)日：1989-04-14
申请号：CS253287
申请日：1987-04-08
Applicant: BASF AG
Inventor： GOERTZ HANS-HELMUT DR , KLIMESCH ROGER G DR , LAEMMERHIRT KLAUS DR , LANG SIEGFRIED DR , SANNER AXEL DR , SPENGLER REINHARD DR
CPC classification number: A61K9/2095 , A61K9/2027 , B29K2105/0035
-
公开(公告)号：CS253287A2
公开(公告)日：1989-04-14
申请号：CS253287
申请日：1987-04-08
Applicant: BASF AG
Inventor： GOERTZ HANS-HELMUT DR , KLIMESCH ROGER G DR , LAEMMERHIRT KLAUS DR , LANG SIEGFRIED DR , SANNER AXEL DR , SPENGLER REINHARD DR
Abstract: Process for the preparation of solid pharmaceutical forms by mixing one or more pharmaceutical active compounds with one or more fusible, pharmacologically tolerated binders and, if required, other conventional pharmaceutical auxiliaries, at from 50 DEG to 180 DEG C., and subjecting the mixture to injection molding or extrusion and shaping, wherein the fusible binder used is a NVP polymer which contains not less than 20% by weight of NVP as copolymerized units, and, where they are present, all of whose comonomers contain nitrogen and/or oxygen.
-
-
-
-
-
-
Search Results
7
records
(took 0.022 seconds)
